Impact on quality of life from multimodality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multimodality treatment in potentially resectable stage III-N2 NSCLC (the PIONEER trial)

INTRODUCTION: Optimal treatment for ‘potentially resectable’ stage III-N2 non-small cell lung cancer (NSCLC) requires multimodality treatment: local treatment (surgery or radiotherapy) and systemic anticancer therapy. There is no clear evidence of superiority for survival between the two approaches...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Sally, Yorke, Janelle, Tsim, Selina, Navani, Neal, Baldwin, David, Woolhouse, Ian, Edwards, John, Grundy, Seamus, Robson, Jonathan, Rhodes, Sarah, Gomes, Fabio, Blackhall, Fiona, Faivre-Finn, Corinne, Evison, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286764/
https://www.ncbi.nlm.nih.gov/pubmed/34266853
http://dx.doi.org/10.1136/bmjresp-2020-000846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286764/
https://www.ncbi.nlm.nih.gov/pubmed/34266853
http://dx.doi.org/10.1136/bmjresp-2020-000846

Ejemplares similares